A Stearyl‐Peptide Based Versatile Strategy to Design Enzyme‐Responsive Liposomes for Targeted Drug Delivery
- 17 November 2026
- journal article
- Published by Wiley in Advanced Healthcare Materials
Abstract
Liposomes are a prominent class of drug delivery nanoparticles. For currently approved liposomal therapeutics, drug is released predominantly via diffusion which has spatio‐temporal kinetic and bioavailability challenges, especially in a dynamic environment. Next‐generation liposome designs focus on stimuli‐triggered enhancement of drug release. One exciting approach here is liposomes that can be site‐specifically destabilized by disease‐associated enzymes. Feasibility of this has been demonstrated with certain phospholipases or metalloproteases, but a versatile strategy for designing liposomes triggerable by any disease‐specific enzyme remains lacking. We report a unique liposome design using enzyme‐cleavable stearyl‐peptide conjugates. Stearylamine has been explored for cationic liposomes in gene delivery, but the cationic charge poses significant cytotoxicity. We demonstrate that conjugating enzyme‐cleavable peptides to stearylamine and assembly of stearyl‐peptide conjugates within liposomes mitigates the cationic charge and significantly enhances biosafety. Surface‐decorating such liposomes with target‐specific ligands enables their active target‐anchorage under flow. Exposure of target‐anchored liposomes to disease‐relevant enzymes renders stearyl‐peptide cleavage and liposome destablization, enhancing drug release. We demonstrate the design versatility utilizing microfluidic models of three different vascular pathologies (hyperfibrinolysis, thrombosis and thromboinflammation) and delivering three corresponding drugs (tranexamic acid, tissue plasminogen activator and deoxyribonulease) triggered by three different enzymes (plasmin, thrombin and neutrophil elastase), respectively.This publication has 83 references indexed in Scilit:
- Development of DNase‐1 Loaded Polymeric Nanoparticles Synthesized by Inverse Flash Nanoprecipitation for Neutrophil‐Mediated Drug Delivery to In Vitro ThrombiAdvanced Healthcare Materials, 2025
- Alteplase or tenecteplase for thrombolysis in ischemic stroke: An illustrated reviewResearch and Practice in Thrombosis and Haemostasis, 2022
- Nanoparticles in the clinic: An update post COVID‐19 vaccinesBioengineering & Translational Medicine, 2021
- Dornase alfa for cystic fibrosisCochrane Database of Systematic Reviews, 2021
- A General Approach to Enzyme‐Responsive LiposomesChemistry – A European Journal, 2020
- Stimuli‐responsive liposomes for drug deliveryWIREs Nanomedicine and Nanobiotechnology, 2017
- Secretory phospholipase A 2 responsive liposomesJournal of Pharmaceutical Sciences, 2011
- Well plate microfluidic system for investigation of dynamic platelet behavior under variable shear loadsBiotechnology and Bioengineering, 2011
- Utilization of Intravenous Tissue Plasminogen Activator for Acute Ischemic StrokeArchives of Neurology, 2004
- Bolus Fibrinolytic Therapy in Acute Myocardial InfarctionJAMA, 2001